[{"orgOrder":0,"company":"CellResearch Corporation","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"Human Umbilical Cord Derived Mesenchymal Stem Cells","moa":"","graph1":"Podiatry","graph2":"Phase I","graph3":"CellResearch Corporation","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"","sponsorNew":"CellResearch Corporation \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"CellResearch Corporation \/ Not Applicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CYP-006TK","moa":"","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Cynata Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Podiatry","country":"","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"CYP-006TK","moa":"","graph1":"Podiatry","graph2":"Phase I","graph3":"Cynata Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Podiatry","amount2New":0,"dosageForm":"Dressing","sponsorNew":"Cynata Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Cynata Therapeutics \/ Not Applicable"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : BR-AC is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.

                          Brand Name : BR-AC

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          October 02, 2024

                          Lead Product(s) : Amniotic Chorion Tissue Allograft

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : Vendaje is a structural tissue allograft composed of the amnion layer of the placental membrane. It is being investigated for diabetic foot ulcers.

                          Brand Name : Vendaje

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          August 21, 2024

                          Lead Product(s) : Amniotic Tissue Allograft

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : The funding aims to accelerate the development of RECCE 327 Gel (R327) for acute treatment of burn wound infections and downstream bacterial complications such as sepsis in a military setting.

                          Brand Name : Recce 327

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          July 16, 2024

                          Lead Product(s) : R327

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : U.S. Department of Defense

                          Deal Size : $2.0 million

                          Deal Type : Funding

                          blank

                          04

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : R327 (RECCE-327) is a fast-acting anti-infective effective against Gram-positive & negative bacteria. It is under development for the treatment of acute bacterial skin and skin structure infections.

                          Brand Name : Recce 327

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          June 25, 2024

                          Lead Product(s) : R327

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : CYP-006TK is a topical wound dressing, cell and gene therapy drug candidate, which is currently being evaluated for the treatment of patients with diabetic foot ulcers.

                          Brand Name : CYP-006TK

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          April 09, 2024

                          Lead Product(s) : CYP-006TK

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          06

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Details : CYP-006TK consists of allogenic mesenchymoangioblast-derived mesenchymal stem cells or Cymerus™ MSCs, seeded onto a heptylamine plasma polymer-coated silicone dressing for diabetic foot ulcers.

                          Brand Name : CYP-006TK

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          February 26, 2024

                          Lead Product(s) : CYP-006TK

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          07

                          Cosmoprof India
                          Not Confirmed
                          Cosmoprof India
                          Not Confirmed

                          Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cells

                          Therapeutic Area : Podiatry

                          Study Phase : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          Details : CorLiCyte® is a live mesenchymal stem cell therapy derived from human umbilical cord lining stem cells, with a proprietary optimised expression of cytokines, growth and cellular factors for the treatment of a number of serious health conditions.

                          Brand Name : CorLiCyte

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 16, 2022

                          Lead Product(s) : Human Umbilical Cord Derived Mesenchymal Stem Cells

                          Therapeutic Area : Podiatry

                          Highest Development Status : Phase I

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank